Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Advanced Or Metastatic Malignancy
• Age: Between 18 years - 100 years
• Gender: Male or Female

• Other Inclusion Criteria:
  

  1) Patients enrolled in the Phase 1a dose escalation portion of the trial must have a histologically or cytologically confirmed advanced malignancy that is metastatic or unresectable. Patients must have received all standard therapy or have been unable to tolerate standard therapy. 2) Patients in the Phase 1b portion of the trial must have a histologically or cytologically confirmed melanoma, NSCLC, GI malignancy with dMMR/MSI-H, or lymphoma that is metastatic or unresectable.
  

You may not be eligible for this study if the following are true:

• 1) Receipt of systemic anticancer therapy including investigational agents or devices within 5 half-lives of the first dose of study treatment. 2) Previous radiotherapy within 14 days of the first dose of study treatment (except for radiation to central nervous system (CNS), which requires a = 28-day washout). 3) Known active central nervous system (CNS) metastasis and/or carcinomatous meningitis.